The class of compounds known as DOCK 10 inhibitors encompasses a group of small molecules that interact with and modulate the activity of the DOCK 10 protein. DOCK 10, a member of the Dedicator of Cytokinesis (DOCK) family of guanine nucleotide exchange factors (GEFs), plays a pivotal role in regulating cell signaling pathways and cytoskeletal dynamics. These inhibitors are designed to bind to specific sites on the DOCK 10 protein, altering its conformation and subsequently influencing its functional activity. DOCK 10, as a GEF, acts as a facilitator for the exchange of GDP (guanosine diphosphate) for GTP (guanosine triphosphate) on Rho GTPases, particularly Rac1 and Cdc42. This exchange is a crucial step in the activation of these GTPases, which in turn regulate various cellular processes such as actin cytoskeleton reorganization, cell migration, and adhesion.
DOCK 10 inhibitors operate by obstructing the nucleotide exchange function of DOCK 10, resulting in the modulation of downstream signaling cascades mediated by Rac1 and Cdc42. This, in turn, influences cellular processes that are reliant on these GTPases' activities, potentially impacting cell motility, morphology, and organization. Researchers have been exploring DOCK 10 inhibitors as tools to dissect the precise contributions of DOCK 10 in cellular processes and to unveil the intricate signaling pathways that it influences. By using these inhibitors, scientists aim to better comprehend the mechanistic intricacies of DOCK 10-mediated cellular functions and the broader implications for cellular physiology. The development and study of DOCK 10 inhibitors shed light on the role of this protein in fundamental cellular processes, opening avenues for unraveling its involvement in normal cellular homeostasis as well as its potential contribution to various diseases or disorders where DOCK 10 dysregulation might play a role.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Tyrosine kinase inhibitor targeting BCR-ABL and c-KIT receptors, used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, employed in non-small cell lung cancer (NSCLC) application. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multi-kinase inhibitor blocking RAF, VEGFR, and PDGFR pathways, used for advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Androgen receptor antagonist that impedes nuclear translocation and DNA binding, applied in metastatic castration-resistant prostate cancer. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Bruton's tyrosine kinase (BTK) inhibitor, employed for B-cell malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
B-cell lymphoma 2 (BCL-2) inhibitor promoting apoptosis, used for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) therapy. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Janus kinase (JAK) inhibitor targeting JAK1 and JAK2. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Poly (ADP-ribose) polymerase (PARP) inhibitor hindering DNA repair, applied in BRCA-mutated ovarian and breast cancer. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
BRAF kinase inhibitor, specifically for the V600E mutation, used in melanoma therapy. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Anaplastic lymphoma kinase (ALK) inhibitor utilized for ALK-positive non-small cell lung cancer (NSCLC). | ||||||